8-K Announcements
6Material company update
Mar 20, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 13, 2026·SEC
TG Therapeutics, Inc.(TGTX)Earnings, Financials & Key Ratios
TGTX•NASDAQ
$36.10
$5.7B mkt cap·240.7× P/E·Price updated May 6, 2026
AboutTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.Show more
- Revenue$329M+40.8%
- EBITDA$42M+100.5%
- Net Income$23M+84.5%
- EPS (Diluted)0.15+75.8%
- Gross Margin88.3%-6.0%
- EBITDA Margin12.83%+42.4%
- Operating Margin12.74%+44.3%
- Net Margin7.11%+31.1%
- ROE12.21%+5.6%
- ROIC13.25%-6.8%
- Debt/Equity1.14+65.3%
- Interest Coverage1.75+6.7%
TGTX Key Insights
TG Therapeutics, Inc. (TGTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 364.6%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Expensive at 26.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TGTX Price & Volume
TG Therapeutics, Inc. (TGTX) stock price & volume — 10-year historical chart
Loading chart...
TGTX Growth Metrics
TG Therapeutics, Inc. (TGTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years115.49%
5 Years364.59%
3 Years266.39%
TTM30.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-36.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-38.15%
Return on Capital
10 Years-122.62%
5 Years-48.95%
3 Years-25.05%
Last Year10.99%
TGTX Recent Earnings
TG Therapeutics, Inc. (TGTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 26, 2026EPS
$0.14
Est $0.35
-60.0%
Revenue
$193M
Est $192M
+0.4%
Q4 2025
Nov 3, 2025EPS
$2.43
Est $0.24
+912.5%
Revenue
$162M
Est $194M
-16.6%
Q3 2025
Aug 4, 2025EPS
$0.17
Est $0.32
-46.9%
Revenue
$141M
Est $146M
-3.5%
Q2 2025
May 5, 2025EPS
$0.03
Est $0.18
-83.3%
Revenue
$121M
Est $134M
-9.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.14vs $0.35-60.0% | $193Mvs $192M+0.4% |
| Q4 2025 | Nov 3, 2025 | $2.43vs $0.24+912.5% | $162Mvs $194M-16.6% |
| Q3 2025 | Aug 4, 2025 | $0.17vs $0.32-46.9% | $141Mvs $146M-3.5% |
| Q2 2025 | May 5, 2025 | $0.03vs $0.18-83.3% | $121Mvs $134M-9.9% |
Based on last 12 quarters of dataView full earnings history →
TGTX Peer Comparison
TG Therapeutics, Inc. (TGTX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 KYMR | 6.75B | 82.71 | -22.41 | -16.72% | -6.12% | -25.02% | 0.05 | |
 VRTX | 107.94B | 424.36 | 27.70 | 9.57% | 35.4% | 23.93% | 2.96% | 0.21 |
 ALKS | 6.12B | 36.25 | 25.35 | -5.25% | 16.37% | 14.45% | 7.85% | 0.04 |
 BIIB | 27.92B | 189.13 | 21.42 | 1.39% | 13.92% | 7.55% | 7.34% | 0.38 |
 GILD | 166.32B | 133.48 | 351.26 | 6.04% | 28.9% | 37.62% | 6.2% | 1.39 |
Compare TGTX vs Peers
TG Therapeutics, Inc. (TGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TGTX Income Statement
TG Therapeutics, Inc. (TGTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 152.38K | 152.38K | 152K | 152K | 152K | 6.69M | 2.79M | 233.66M | 329M | 454.07M |
| Revenue Growth % | 0% | 0% | -0.25% | 0% | 0% | 4300.66% | -58.36% | 8290.02% | 40.8% | 30.96% |
| Cost of Goods Sold | 62.96K | 82.36K | 88K | 0 | 0 | 790K | 265K | 14.13M | 38.49M | 59.22M |
| COGS % of Revenue | 41.32% | 54.05% | 57.89% | - | - | 11.81% | 9.52% | 6.05% | 11.7% | - |
| Gross Profit | 89.42K▲ 0% | 70.03K▼ 21.7% | 64K▼ 8.6% | 152K▲ 137.5% | 152K▲ 0.0% | 5.9M▲ 3780.9% | 2.52M▼ 57.3% | 219.53M▲ 8611.5% | 290.52M▲ 32.3% | 394.85M▲ 0% |
| Gross Margin % | 58.68% | 45.95% | 42.11% | 100% | 100% | 88.19% | 90.48% | 93.95% | 88.3% | 86.96% |
| Gross Profit Growth % | -41.32% | -21.69% | -8.61% | 137.5% | 0% | 3780.92% | -57.28% | 8611.55% | 32.34% | - |
| Operating Expenses | 79.12M | 118.86M | 174.55M | 169.21M | 273.75M | 350.67M | 220.84M | 198.9M | 248.59M | 309M |
| OpEx % of Revenue | 51923.47% | 78004.56% | 114836.84% | 111320.39% | 180096.05% | 5242.47% | 7929.48% | 85.12% | 75.56% | - |
| Selling, General & Admin | 9.89M | 16.33M | 15.16M | 15.03M | 107.85M | 128.09M | 95.48M | 122.71M | 154.3M | 186.84M |
| SG&A % of Revenue | 6489.65% | 10717.22% | 9974.34% | 9886.18% | 70953.95% | 1914.93% | 3428.51% | 52.51% | 46.9% | - |
| Research & Development | 66.49M | 96.89M | 153.79M | 154.18M | 165.9M | 222.58M | 125.35M | 76.19M | 94.29M | 122.16M |
| R&D % of Revenue | 43633.93% | 63581.51% | 101179.61% | 101434.21% | 109142.11% | 3327.54% | 4500.97% | 32.61% | 28.66% | - |
| Other Operating Expenses | 393.2K | -58.74K | 61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -78.97M▲ 0% | -118.71M▼ 50.3% | -174.4M▼ 46.9% | -169.06M▲ 3.1% | -273.59M▼ 61.8% | -344.77M▼ 26.0% | -218.32M▲ 36.7% | 20.63M▲ 109.5% | 41.93M▲ 103.2% | 85.85M▲ 0% |
| Operating Margin % | -51823.47% | -77904.56% | -114736.84% | -111220.39% | -179996.05% | -5154.28% | -7838.99% | 8.83% | 12.74% | 18.91% |
| Operating Income Growth % | -24.99% | -50.33% | -46.91% | 3.06% | -61.84% | -26.02% | 36.68% | 109.45% | 103.21% | - |
| EBITDA | -78.91M | -118.63M | -174.31M | -168.77M | -273.22M | -344.28M | -217.8M | 21.06M | 42.21M | 86.09M |
| EBITDA Margin % | -51782.16% | -77850.52% | -114678.95% | -111034.87% | -179750% | -5146.9% | -7820.5% | 9.01% | 12.83% | 18.96% |
| EBITDA Growth % | -24.92% | -50.34% | -46.94% | 3.18% | -61.89% | -26.01% | 36.74% | 109.67% | 100.46% | -15.78% |
| D&A (Non-Cash Add-back) | 62.96K | 82.36K | 88K | 282K | 374K | 494K | 515K | 423K | 280K | 241K |
| EBIT | -78.97M | -117.63M | -172.6M | -167.58M | -273.05M | -342.46M | -213.62M | 25.68M | 49.62M | 97.47M |
| Net Interest Income | 323K | -845K | -877K | -5.29M | -6.33M | -5.64M | -10.19M | -12.62M | -24.03M | -31.37M |
| Interest Income | 323.03K | 294.48K | 857K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 1.14M | 1.73M | 5.29M | 6.33M | 5.64M | 10.19M | 12.62M | 24.03M | 31.37M |
| Other Income/Expense | 716K | 235.99K | 918K | -3.82M | -5.79M | -3.33M | -5.5M | -7.57M | -16.34M | -19.74M |
| Pretax Income | -78.25M▲ 0% | -118.48M▼ 51.4% | -173.48M▼ 46.4% | -172.87M▲ 0.4% | -279.38M▼ 61.6% | -348.1M▼ 24.6% | -223.81M▲ 35.7% | 13.06M▲ 105.8% | 25.59M▲ 95.9% | 66.11M▲ 0% |
| Pretax Margin % | -51353.45% | -77749.86% | -114132.89% | -113730.92% | -183803.29% | -5204.08% | -8036.34% | 5.59% | 7.78% | 14.56% |
| Income Tax | -716.23K | -235.74K | -918K | 0 | 0 | 0 | 0 | 390K | 2.21M | 5.65M |
| Effective Tax Rate % | 0.92% | 0.2% | 0.53% | 0% | 0% | 0% | 0% | 2.99% | 8.64% | 8.55% |
| Net Income | -78.25M▲ 0% | -118.48M▼ 51.4% | -173.48M▼ 46.4% | -172.87M▲ 0.4% | -279.38M▼ 61.6% | -348.1M▼ 24.6% | -223.81M▲ 35.7% | 12.67M▲ 105.7% | 23.38M▲ 84.5% | 60.46M▲ 0% |
| Net Margin % | -51353.45% | -77749.86% | -114132.89% | -113730.92% | -183803.29% | -5204.08% | -8036.34% | 5.42% | 7.11% | 13.31% |
| Net Income Growth % | -24.31% | -51.4% | -46.43% | 0.35% | -61.61% | -24.6% | 35.7% | 105.66% | 84.52% | -36.82% |
| Net Income (Continuing) | -78.25M | -118.48M | -173.48M | -172.87M | -279.38M | -348.1M | -223.81M | 12.67M | 23.38M | 60.46M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.60▲ 0% | -1.91▼ 19.4% | -2.30▼ 20.4% | -1.96▲ 14.8% | -2.42▼ 23.5% | -2.63▼ 8.7% | -1.46▲ 44.5% | 0.09▲ 105.8% | 0.15▲ 75.8% | 0.37▲ 0% |
| EPS Growth % | -15.94% | -19.38% | -20.42% | 14.78% | -23.47% | -8.68% | 44.49% | 105.84% | 75.85% | -38.15% |
| EPS (Basic) | -1.60 | -1.91 | -2.30 | -1.96 | -2.42 | -2.63 | -1.46 | 0.09 | 0.16 | - |
| Diluted Shares Outstanding | 49.04M | 62.07M | 75.47M | 88.37M | 115.33M | 132.22M | 135.41M | 148.51M | 160.34M | 162.56M |
| Basic Shares Outstanding | 49.04M | 62.07M | 75.47M | 88.37M | 115.33M | 132.22M | 135.41M | 141.96M | 145.32M | 146.74M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TGTX Balance Sheet
TG Therapeutics, Inc. (TGTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 50.86M | 93.32M | 79.03M | 149.15M | 611.74M | 330.96M | 168.27M | 317.94M | 566.36M | 663.96M |
| Cash & Short-Term Investments | 44.97M | 84.83M | 68.81M | 140.44M | 605.43M | 314.76M | 161.68M | 217.51M | 311M | 251.87M |
| Cash Only | 25.03M | 56.72M | 41.96M | 112.64M | 553.44M | 298.89M | 102.3M | 92.93M | 179.89M | 129.13M |
| Short-Term Investments | 19.85M | 28M | 26.85M | 27.8M | 51.99M | 15.88M | 59.37M | 124.58M | 131.11M | 122.74M |
| Accounts Receivable | 83.85K | 108.47K | 95K | 0 | 0 | 1.39M | 0 | 51.09M | 129.19M | 231.52M |
| Days Sales Outstanding | 200.85 | 259.81 | 228.13 | - | - | 75.79 | - | 79.81 | 143.32 | 133.95 |
| Inventory | 5.59M | 7.95M | 9.69M | 0 | 0 | 0 | 0 | 39.82M | 110.46M | 155.2M |
| Days Inventory Outstanding | 32.44K | 35.22K | 40.2K | - | - | - | - | 1.03K | 1.05K | 782.91 |
| Other Current Assets | 216.4K | 328.32K | 344K | 611K | 1.08M | 2.88M | 2.36M | 5.34M | 15.72M | 25.37M |
| Total Non-Current Assets | 3.92M | 4.06M | 4.58M | 13.86M | 13.9M | 48.66M | 25.3M | 11.64M | 11.33M | 38.65M |
| Property, Plant & Equipment | 2.37M | 2.68M | 2.54M | 11.81M | 11.84M | 11.07M | 10.82M | 8.05M | 7.15M | 6.72M |
| Fixed Asset Turnover | 0.06x | 0.06x | 0.06x | 0.01x | 0.01x | 0.60x | 0.26x | 29.03x | 46.01x | 64.39x |
| Goodwill | 799.39K | 799.39K | 799K | 799K | 799K | 799K | 799K | 799K | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 583.21K | 587.29K | 1.24M | 0 | 0 | 35.53M | 12.4M | 0 | 808K | 32.43M |
| Other Non-Current Assets | 747.58K | 587.29K | 1.24M | 1.25M | 1.26M | 1.26M | 1.27M | 2.79M | 3.37M | 13.47M |
| Total Assets | 54.78M▲ 0% | 97.38M▲ 77.8% | 83.62M▼ 14.1% | 163.01M▲ 95.0% | 625.64M▲ 283.8% | 379.63M▼ 39.3% | 193.57M▼ 49.0% | 329.59M▲ 70.3% | 577.69M▲ 75.3% | 702.61M▲ 0% |
| Asset Turnover | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x | 0.01x | 0.71x | 0.57x | 0.72x |
| Asset Growth % | -51.72% | 77.76% | -14.14% | 94.96% | 283.8% | -39.32% | -49.01% | 70.27% | 75.28% | 303.31% |
| Total Current Liabilities | 16.88M | 27.96M | 38.85M | 84.45M | 87.55M | 65.38M | 53.2M | 53.72M | 90.68M | 171.89M |
| Accounts Payable | 15.27M | 25.88M | 36.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | 88.51K | 114.69K | 150.88K | - | - | - | - | - | - | - |
| Short-Term Debt | 68.88K | 127.61K | 67K | 0 | 22.18M | 975K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 152.38K | 152.38K | 152K | 0 | 0 | 0 | 0 | 152K | 11.41M | 61.5M |
| Other Current Liabilities | 0 | 0 | 0 | 82.83M | 63.71M | 62.97M | 51.62M | 52.12M | 78.11M | 146.89M |
| Current Ratio | 3.01x | 3.34x | 2.03x | 1.77x | 6.99x | 5.06x | 3.16x | 5.92x | 6.25x | 6.25x |
| Quick Ratio | 2.68x | 3.05x | 1.78x | 1.77x | 6.99x | 5.06x | 3.16x | 5.18x | 5.03x | 5.03x |
| Cash Conversion Cycle | -55.88K | -79.21K | -110.46K | - | - | - | - | - | - | 916.86 |
| Total Non-Current Liabilities | 2.04M | 2.43M | 20.73M | 39.95M | 18.74M | 77.09M | 81.78M | 115.36M | 264.65M | 254.29M |
| Long-Term Debt | 0 | 0 | 0 | 28.97M | 7.72M | 66.79M | 71.14M | 100.12M | 244.43M | 245.04M |
| Capital Lease Obligations | 0 | 0 | 0 | 10.22M | 10.41M | 9.85M | 10.34M | 9.23M | 8.13M | 32M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 816.26K | 1.36M | 19.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 54.78M | 97.38M | 59.58M | 124.4M | 106.29M | 142.48M | 134.99M | 169.09M | 355.33M | 426.18M |
| Total Debt | 68.88K | 127.61K | 67K | 40.8M | 41.98M | 79.05M | 83.06M | 110.8M | 253.72M | 253.72M |
| Net Debt | -24.96M | -56.59M | -41.89M | -71.83M | -511.46M | -219.84M | -19.24M | 17.86M | 73.83M | 124.59M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 1.06x | 0.08x | 0.33x | 1.42x | 0.69x | 1.14x | 1.14x |
| Debt / EBITDA | - | - | - | - | - | - | - | 5.26x | 6.01x | 2.95x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.85x | 1.75x | 1.75x |
| Interest Coverage | - | -104.18x | -100.58x | -31.98x | -43.23x | -61.15x | -21.42x | 1.64x | 1.75x | 3.11x |
| Total Equity | 35.87M▲ 0% | 66.99M▲ 86.8% | 24.04M▼ 64.1% | 38.62M▲ 60.7% | 519.35M▲ 1244.9% | 237.15M▼ 54.3% | 58.59M▼ 75.3% | 160.5M▲ 174.0% | 222.36M▲ 38.5% | 276.43M▲ 0% |
| Equity Growth % | -64.69% | 86.78% | -64.12% | 60.65% | 1244.94% | -54.34% | -75.3% | 173.95% | 38.54% | 159.05% |
| Book Value per Share | 0.73 | 1.08 | 0.32 | 0.44 | 4.50 | 1.79 | 0.43 | 1.08 | 1.39 | 1.70 |
| Total Shareholders' Equity | 35.87M | 66.99M | 24.04M | 38.62M | 519.35M | 237.15M | 58.59M | 160.5M | 222.36M | 276.43M |
| Common Stock | 56.82K | 73.18K | 84K | 109K | 141K | 143K | 146K | 151K | 156K | 159K |
| Retained Earnings | -236.39M | -354.86M | -528.35M | -701.22M | -980.6M | -1.33B | -1.53B | -1.55B | -1.53B | -1.5B |
| Treasury Stock | -234.34K | -234.34K | -234K | -234K | -234K | -234K | -234K | -234K | -8.99M | -21.99M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TGTX Cash Flow Statement
TG Therapeutics, Inc. (TGTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -61.59M | -93.76M | -128.93M | -132.81M | -214.51M | -295.63M | -176.17M | -31.41M | -40.52M | -40.52M |
| Operating CF Margin % | -40419.3% | -61532.32% | -84819.08% | -87372.37% | -141123.03% | -4419.7% | -6325.67% | -13.44% | -12.31% | - |
| Operating CF Growth % | -37.82% | -52.23% | -37.5% | -3.01% | -61.52% | -37.82% | 40.41% | 82.17% | -28.98% | -424.25% |
| Net Income | -78.25M | -118.48M | -173.48M | -172.87M | -279.38M | -348.1M | -198.34M | 12.67M | 23.38M | 60.46M |
| Depreciation & Amortization | 62.96K | 82.36K | 88K | 282K | 374K | 494K | 515K | 423K | 280K | 241K |
| Stock-Based Compensation | 7.51M | 15.95M | 12.89M | 11.34M | 80.29M | 61.27M | 19.18M | 37.93M | 42.54M | 55.05M |
| Deferred Taxes | 5.84B | 61.32K | -119K | -257K | -30K | 517K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -5.84B | 58.74K | 3.94M | 3.52M | 4M | 2.4M | 4.11M | 2.22M | 2.58M | 2.97M |
| Working Capital Changes | 8.77M | 8.56M | 27.76M | 25.19M | -19.76M | -12.22M | -1.65M | -84.66M | -109.3M | -177.85M |
| Change in Receivables | 102.17K | -24.62K | 14K | -11K | -6K | -1.39M | 1.39M | -51.09M | -78.09M | -147.91M |
| Change in Inventory | 0 | 0 | 0 | 11K | 6K | -15.99M | 0 | -36.94M | -66.85M | -70.07M |
| Change in Payables | 6.49M | 11.02M | 10.96M | -4.79M | 11.63M | 15.99M | -11.01M | 192K | 0 | 71.15M |
| Cash from Investing | 26.55M | -8.21M | 1.18M | -718K | -24.51M | -332K | -20.01M | -50.65M | -1.04M | -10.47M |
| Capital Expenditures | -343.99K | -2.23K | -90K | -131K | -357K | -401K | -14K | 0 | -45K | -112K |
| CapEx % of Revenue | 225.74% | 1.46% | 59.21% | 86.18% | 234.87% | 5.99% | 0.5% | - | 0.01% | - |
| Acquisitions | 0 | 0 | 0 | 587K | 24.15M | -69K | 20M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 26.89M | -8.21M | 1.27M | -587K | -24.15M | 69K | -20M | 0 | 0 | 0 |
| Cash from Financing | 5.02M | 133.66M | 113.64M | 204.21M | 679.83M | 41.42M | -391K | 72.7M | 128.53M | 115.84M |
| Debt Issued (Net) | 0 | 0 | 0 | 29.99M | 0 | 40M | -975K | 25M | 137.26M | 137.26M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 584K | 1000K | -1000K | -4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.76M | -21.76M |
| Other Financing | -13.47K | 0 | 0 | -795K | 147K | -800K | 0 | 1.41M | 25K | 333K |
| Net Change in Cash | -30.03M▲ 0% | 31.69M▲ 205.5% | -14.11M▼ 144.5% | 70.69M▲ 601.1% | 440.81M▲ 523.6% | -254.55M▼ 157.7% | -196.57M▲ 22.8% | -9.36M▲ 95.2% | 86.97M▲ 1029.3% | 46.24M▲ 0% |
| Free Cash Flow | -61.94M▲ 0% | -93.77M▼ 51.4% | -129.01M▼ 37.6% | -132.94M▼ 3.0% | -214.86M▼ 61.6% | -296.04M▼ 37.8% | -176.18M▲ 40.5% | -31.41M▲ 82.2% | -40.56M▼ 29.1% | -59.24M▲ 0% |
| FCF Margin % | -40645.04% | -61533.78% | -84878.29% | -87458.55% | -141357.89% | -4425.7% | -6326.18% | -13.44% | -12.33% | -13.05% |
| FCF Growth % | -38.46% | -51.39% | -37.59% | -3.04% | -61.63% | -37.78% | 40.49% | 82.17% | -29.12% | -187.34% |
| FCF per Share | -1.26 | -1.51 | -1.71 | -1.50 | -1.86 | -2.24 | -1.30 | -0.21 | -0.25 | -0.25 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.79x | 0.74x | 0.77x | 0.77x | 0.85x | 0.79x | -2.48x | -1.73x | -0.98x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.47M | 19.63M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500K | 0 |
TGTX Key Ratios
TG Therapeutics, Inc. (TGTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -113.87% | -230.36% | -381.16% | -551.85% | -100.14% | -92.03% | -151.36% | 11.57% | 12.21% | 21.87% |
| Return on Invested Capital (ROIC) | -205.55% | -835.68% | - | - | - | -2052.2% | -578% | 14.22% | 13.25% | 13.25% |
| Gross Margin | 58.68% | 45.95% | 42.11% | 100% | 100% | 88.19% | 90.48% | 93.95% | 88.3% | 86.96% |
| Net Margin | -51353.45% | -77749.86% | -114132.89% | -113730.92% | -183803.29% | -5204.08% | -8036.34% | 5.42% | 7.11% | 13.31% |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 1.06x | 0.08x | 0.33x | 1.42x | 0.69x | 1.14x | 1.14x |
| Interest Coverage | - | -104.18x | -100.58x | -31.98x | -43.23x | -61.15x | -21.42x | 1.64x | 1.75x | 3.11x |
| FCF Conversion | 0.79x | 0.79x | 0.74x | 0.77x | 0.77x | 0.85x | 0.79x | -2.48x | -1.73x | -0.98x |
| Revenue Growth | 0% | 0% | -0.25% | 0% | 0% | 4300.66% | -58.36% | 8290.02% | 40.8% | 30.96% |
TGTX SEC Filings & Documents
TG Therapeutics, Inc. (TGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TGTX Frequently Asked Questions
TG Therapeutics, Inc. (TGTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TG Therapeutics, Inc. (TGTX) reported $454.1M in revenue for fiscal year 2024. This represents a 453968% increase from $0.1M in 1996.
TG Therapeutics, Inc. (TGTX) grew revenue by 40.8% over the past year. This is strong growth.
Yes, TG Therapeutics, Inc. (TGTX) is profitable, generating $60.5M in net income for fiscal year 2024 (7.1% net margin).
Dividend & Returns
TG Therapeutics, Inc. (TGTX) has a return on equity (ROE) of 12.2%. This is reasonable for most industries.
TG Therapeutics, Inc. (TGTX) had negative free cash flow of $59.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More TGTX
TG Therapeutics, Inc. (TGTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates